and biosimilar medications
available at fair prices
Growing U.S. manufacturing capability
Our new 140,000 square-foot sterile injectable manufacturing facility will produce:
- Essential medicines for hospitals across the U.S.
- Insulins that account for the majority of daily use in the U.S.
Our Petersburg facility, just outside of Richmond, Virginia, has the capacity to produce 90 million vials and 50 million pre-filled syringes of essential medications per year. We are also building a high-speed filling line for additional pre-filled insulin pen capacity.
Our filling lines protect the integrity of medications inside isolators, requiring very little human intervention compared with older technology facilities where many drugs are produced today. We use disposable systems for efficient line changeover, further reducing risk of contamination. Our packaging line is fully compliant with the FDA’s Drug Supply Chain Security Act (DSCSA).
Approximately three dozen Abbreviated New Drug Applications (ANDAs) are now in development. These medications are prioritized for production by our members.
We will also continue to partner with like-minded quality generic drug manufacturers to ensure patients have the medications they need when they need them.
Nearly 80 quality generic medications accessible to member hospitals
- Pain management
- Opioid reversal agent
- General anesthetic
- Local anesthetic
- Neuromuscular blocker
- Neuromuscular blocker reversal agent
- Catecholamine (anti-hypotensive)
Increasing access to affordable medications at the pharmacy counter
CivicaScript brings much needed market competition to help drive down prices for consumers. With the launch of our medication to help treat prostate cancer, CivicaScript has made this vital medicine available and affordable at a fraction of its market cost.
Making affordable insulin a reality
Ending the life-threatening practice of insulin rationing.
Civica is preparing to manufacture and distribute biosimilar insulins.
The consistent availability of affordable insulin will benefit people who ration their care or who have been forced to choose between this life-sustaining medicine and living expenses. Those who are uninsured or underinsured often pay the most out of pocket for their medications.
Long- and short-acting insulins will be produced and available in both vials and pre-filled pens.
Radical price transparency
Our insulins will be offered at a single transparent price available to any purchaser, without the hidden rebates and unfair markups that harm consumers.
We will set a recommended price to the consumer of no more than $30 per vial and no more than $55 for a box of five pre-filled pens.
For people, not profits
From the start, our goal in entering the insulin space has been market impact. It is positive news that others have indicated they will roll back their predatory high prices. The opportunity now is to continue the momentum of price reductions. Our existence as a quality insulin supplier will ensure that happens.
Join Civica and help eradicate drug shortages.